HUTCHMED (China) Ltd
HCM17.040USD
-0.410-2.35%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
14.86BMarket Cap
--P/E TTM
More Details of HUTCHMED (China) Ltd Company
HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.
Company Info
Ticker SymbolHCM
Company nameHUTCHMED (China) Ltd
IPO dateMay 19, 2006
CEODr. Weiguo Su, Ph.D.
Number of employees1811
Security typeOrdinary Share
Fiscal year-endMay 19
Address48th Floor, Cheung Kong Center, 2 Queen's Road Central
City
Stock exchangeHochiminh Stock Exchange
CountryHong Kong
Postal code- -
Phone85221281188
Websitehttps://www.hutch-med.com/
Ticker SymbolHCM
IPO dateMay 19, 2006
CEODr. Weiguo Su, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Chig Fung (Johnny) Cheng
Mr. Chig Fung (Johnny) Cheng
Acting Chief Executive Officer, Chief Financial Officer, Executive Director
Acting Chief Executive Officer, Chief Financial Officer, Executive Director
33.74K
--
Dr. Dan Eldar, Ph.D.
Dr. Dan Eldar, Ph.D.
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Dr. Chaohong (Mary) Hu
Dr. Chaohong (Mary) Hu
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Kin Hung (Mark) Lee
Mr. Kin Hung (Mark) Lee
Senior Vice President - Corporate Management and Communications
Senior Vice President - Corporate Management and Communications
--
--
Prof. Shu Kam (Tony) Mok
Prof. Shu Kam (Tony) Mok
Senior Lead Non-Executive Independent Director
Senior Lead Non-Executive Independent Director
--
--
Mr. David Ng
Mr. David Ng
Vice President
Vice President
--
--
Ms. Ling Yang
Ms. Ling Yang
Non-Executive Director
Non-Executive Director
--
--
Dr. Weiguo Su, Ph.D.
Dr. Weiguo Su, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
--
--
Dr. Zhenping Wu, Ph.D.
Dr. Zhenping Wu, Ph.D.
Executive Vice President - Pharmaceutical Sciences and Manufacturing
Executive Vice President - Pharmaceutical Sciences and Manufacturing
--
--
Dr. Qingmei (May) Wang, Ph.D.
Dr. Qingmei (May) Wang, Ph.D.
Senior Vice President - Business Development and Strategic Alliances
Senior Vice President - Business Development and Strategic Alliances
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Chig Fung (Johnny) Cheng
Mr. Chig Fung (Johnny) Cheng
Acting Chief Executive Officer, Chief Financial Officer, Executive Director
Acting Chief Executive Officer, Chief Financial Officer, Executive Director
33.74K
--
Dr. Dan Eldar, Ph.D.
Dr. Dan Eldar, Ph.D.
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Dr. Chaohong (Mary) Hu
Dr. Chaohong (Mary) Hu
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Kin Hung (Mark) Lee
Mr. Kin Hung (Mark) Lee
Senior Vice President - Corporate Management and Communications
Senior Vice President - Corporate Management and Communications
--
--
Prof. Shu Kam (Tony) Mok
Prof. Shu Kam (Tony) Mok
Senior Lead Non-Executive Independent Director
Senior Lead Non-Executive Independent Director
--
--
Mr. David Ng
Mr. David Ng
Vice President
Vice President
--
--
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2024
FY2023
FY2022
FY2021
FY2020
No Data
By RegionUSD
Name
Revenue
Proportion
PRC
630.20M
0.00%
Unallocated
0.00
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Mon, Aug 18
Updated: Mon, Aug 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Schroder Investment Management (Singapore) Ltd.
1.02%
Allianz Global Investors Asia Pacific Limited
0.50%
Schroder Investment Management (Hong Kong) Ltd.
0.46%
State Street Global Advisors (US)
0.19%
AIA Group Ltd
0.18%
Other
97.65%
Shareholders
Shareholders
Proportion
Schroder Investment Management (Singapore) Ltd.
1.02%
Allianz Global Investors Asia Pacific Limited
0.50%
Schroder Investment Management (Hong Kong) Ltd.
0.46%
State Street Global Advisors (US)
0.19%
AIA Group Ltd
0.18%
Other
97.65%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
2.38%
Investment Advisor
0.70%
Research Firm
0.30%
Hedge Fund
0.24%
Individual Investor
0.12%
Sovereign Wealth Fund
0.01%
Other
96.25%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
160
6.97M
3.99%
-6.31M
2025Q1
166
6.98M
4.00%
-6.73M
2024Q4
187
7.28M
4.18%
-8.01M
2024Q3
259
7.73M
4.44%
-16.35M
2024Q2
280
9.29M
5.33%
-17.79M
2024Q1
306
15.01M
8.61%
-19.39M
2023Q4
327
16.63M
9.55%
-27.28M
2023Q3
339
25.00M
14.36%
-20.50M
2023Q2
352
26.00M
15.01%
-20.74M
2023Q1
364
26.52M
15.33%
-22.52M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Schroder Investment Management (Singapore) Ltd.
1.87M
1.07%
+570.74K
+43.88%
Mar 31, 2025
Allianz Global Investors Asia Pacific Limited
945.74K
0.54%
-117.52K
-11.05%
Mar 31, 2025
Schroder Investment Management (Hong Kong) Ltd.
972.00K
0.56%
-496.17K
-33.80%
Mar 31, 2025
State Street Global Advisors (US)
336.87K
0.19%
-10.74K
-3.09%
Mar 31, 2025
AIA Group Ltd
315.44K
0.18%
--
--
Mar 31, 2025
Goldman Sachs & Company, Inc.
93.92K
0.05%
+7.34K
+8.48%
Mar 31, 2025
M&G Investment Management Ltd.
258.69K
0.15%
-7.09K
-2.67%
Mar 31, 2025
Su (Weiguo Ph.D.)
183.98K
0.11%
+183.98K
--
Mar 04, 2024
Jane Street Capital, L.L.C.
222.24K
0.13%
+124.77K
+128.01%
Mar 31, 2025
Amundi Asset Management, SAS
157.43K
0.09%
-12.82K
-7.53%
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
